drugset / Trial / NCT05866627

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

NCT05866627

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.

Timeline

Start
2023-07-04
Primary completion
2023-09-29
Completion
2023-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Afimetoran Small molecule
Subject Famotidine Other / unclassified

Indications

No indication recorded.